In part 2B, rucaparib was tested in patients with relapsed high-grade ovarian cancer (HGOC) with a germline or somatic BRCA1/2 mutation (g/sBRCAm) who had received at least three cycles of prior chemotherapy. This evidence concerns the gene BRCA1 and ovarian carcinoma.